Mental health landscape in Kosova from 2017 to 2022: A retrospective study of antidepressant and anxiolytic market trends and the impact of COVID-19

Ardian Rugova,Manushaqe Kryeziu-Rrahmani,Genta Jahiu,Nazim Dakaj,Fehmi Rrahmani,Nderim Kryeziu
DOI: https://doi.org/10.1016/j.jpsychores.2024.111927
IF: 4.62
2024-09-09
Journal of Psychosomatic Research
Abstract:Objectives This study explores the mental health situation in Kosova and the impact of the COVID-19 pandemic. Methods Marketed quantities of antidepressants (N06A) and anxiolytics (N05B) from 2017 to 2022 were analyzed using the Anatomical Therapeutic Chemical/Defined Daily Doses (ATC/DDD) methodology. Caution is advised as these quantities may not directly reflect patient usage and could include uses for conditions outside their primary indications. Results Prior to the pandemic, antidepressant quantities remained relatively stable, but rose from 6.8 DDD/1000 inhabitants/day in 2019 to 9.7 in 2020 and 12.4 in 2021, before returning to pre-pandemic levels of 6.8 DDD in 2022. Over 80 % of these were selective serotonin reuptake inhibitors. Meanwhile, anxiolytic quantities initially decreased from 17.4 DDD in 2017 to 9.9 in 2019, then rebounded to 17.9 DDD in 2020. Notably, alprazolam usage surged from 2.9 in 2017 to 6.9 in 2021, subsequently dropping to 2.0 in 2022. Conclusions The volatile trends in medication quantities during the pandemic suggest a fragile mental health landscape in Kosova—a developing, post-conflict country with a youthful population—underscoring the need for proactive interventions in similar contexts globally.
psychiatry
What problem does this paper attempt to address?